Overview

  • Product name
    ABT-737, BH3 mimetic Bcl-xL, Bcl-2 and Bcl-w inhibitor
  • Description
    BH3 mimetic Bcl-xL, Bcl-2 and Bcl-w inhibitor
  • Biological description
    BH3 mimetic Bcl-xL, Bcl-2 and Bcl-w inhibitor. Triggers Bax/Bak-mediated apoptosis (EC50 values are 79, 30 and 198 nM for Bcl-xL, Bcl-2 and Bcl-w mediated apoptosis respectively). Shows antitumor effects in vivo.
  • Purity
    > 95%
  • CAS Number
    852808-04-9
  • Chemical structure
    Chemical Structure

Properties

Images

  • MI-63 acts synergistically with ABT-737.

    Panel A. The combination of MI-63 and ABT-737 was studied in wild-type p53 MM1.S and MOLP-8 cells (left panel), and in mutant RPMI 8226 and U266 cells (right panel). Multiple doses of each drug were used for this experiment, with one representative condition shown. *p<0.005, ** p<0.05.

References

This product has been referenced in:
  • Yang MC  et al. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: A prospective combination of ABT-737 and TMZ for treating glioma. Int J Oncol : (2015). Read more (PubMed: 25586056) »
  • Gu D  et al. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One 9:e103015 (2014). Read more (PubMed: 25181509) »
  • van Delft MF  et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-99 (2006). Read more (PubMed: 17097561) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141336.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up